Open Access

Bendamustine: A review of pharmacology, clinical use and immunological effects (Review)

  • Authors:
    • Hrvoje Lalic
    • Igor Aurer
    • Drago Batinic
    • Dora Visnjic
    • Tomislav Smoljo
    • Antonija Babic
  • View Affiliations

  • Published online on: May 3, 2022     https://doi.org/10.3892/or.2022.8325
  • Article Number: 114
  • Copyright: © Lalic et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatment of chronic lymphocytic leukemia and indolent B‑cell non‑Hodgkin lymphoma. Considering its beneficial properties in the therapy of relapsed or refractory hematological malignancies, synergistic effects with other antineoplastic agents and increasing recent reports on its immunomodulatory effects, bendamustine has once again gained its justified attention. The uniqueness of bendamustine‑mediated effects should be observed keeping in mind its distinctive structure with structural similarities to both alkylating agents and purine analogs. In the present review, the current knowledge on the use of bendamustine in oncology, its pharmacokinetics, mechanism of action and toxicity was summarized. In addition, its immune‑modulating effects that have not been fully elucidated so far are emphasized, hoping to encourage further investigations of this unique drug.

Related Articles

Journal Cover

June-2022
Volume 47 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T and Babic A: Bendamustine: A review of pharmacology, clinical use and immunological effects (Review). Oncol Rep 47: 114, 2022
APA
Lalic, H., Aurer, I., Batinic, D., Visnjic, D., Smoljo, T., & Babic, A. (2022). Bendamustine: A review of pharmacology, clinical use and immunological effects (Review). Oncology Reports, 47, 114. https://doi.org/10.3892/or.2022.8325
MLA
Lalic, H., Aurer, I., Batinic, D., Visnjic, D., Smoljo, T., Babic, A."Bendamustine: A review of pharmacology, clinical use and immunological effects (Review)". Oncology Reports 47.6 (2022): 114.
Chicago
Lalic, H., Aurer, I., Batinic, D., Visnjic, D., Smoljo, T., Babic, A."Bendamustine: A review of pharmacology, clinical use and immunological effects (Review)". Oncology Reports 47, no. 6 (2022): 114. https://doi.org/10.3892/or.2022.8325